Exploring market dynamics of biological including biosimilar treatments for retinal diseases in Europe: An interrupted time‐series analysis
Acta Ophthalmologica · 2026-12 · 104 (8) · 926-939
DOI: 10.1111/aos.70148 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Acta Ophthalmologica, online erschienen am 30.04.2026. Verfasst von Elif Car und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium. Hauptthemen laut MEDLINE: Biosimilar Pharmaceuticals, Ranibizumab, Retinal Diseases, Recombinant Fusion Proteins. Die Arbeit nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: KU Leuven and the Market Analysis of Biologics and Biosimilars following Loss of Exclusivity (MABEL) Fund.
Abstract (Originalsprache)
Purpose
To assess the impact of biosimilar ranibizumab and on‐patent faricimab market entry on pricing and utilization trends and describe national variation in off‐label bevacizumab use in Europe.
Methods
Interrupted time series analysis of quarterly sales data (Q1 2018–Q2 2024) in 11 European countries evaluated ranibizumab utilization and price after biosimilar entry and aflibercept utilization after faricimab entry. A cross‐country survey assessed off‐label bevacizumab use.
Results
Ranibizumab utilization declined in seven of 11 countries (−1.0% to −29.8%) despite biosimilar entry and associated price reductions. Significant negative trend changes in ranibizumab utilization were observed in France (−0.449; p < 0.001), Germany (−3.935; p = 0.021) and Spain (−8.648; p = 0.002), while Hungary (+33.7; p < 0.001) and the UK (+3.4; p = 0.005) showed increases. Negative trend changes in ranibizumab's weighted average price per TD were observed in four countries ranging from € −0.083 ( p < 0.001) in Germany to € −1.309 ( p < 0.001) in Hungary. Aflibercept utilization increased across all countries during the study period (+23.6% to +243.3%), but subsequent to faricimab entry, downward utilization trends were observed in several countries, indicating a shift in market dynamics potentially due to extended dosing intervals. Survey results revealed substantial heterogeneity in off‐label bevacizumab use, reimbursement status, liability attribution and compounding practises, underscoring fragmented policy environments that influence treatment access.
Conclusion
The study found substantial cross‐country variation in anti‐VEGF utilization in Europe. Coordinated policy action is needed to support a sustainable biosimilar uptake in this evolving market.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium.
- Hospital Pharmacy, Erasmus University Medical Center, Rotterdam, The Netherlands.
ORCID-Profile: Elif Car
Förderung
- KU Leuven and the Market Analysis of Biologics and Biosimilars following Loss of Exclusivity (MABEL) Fund
Zitieren
APA
Car, E., Huys, I., Simoens, S., & Vulto, A. G. (2026). Exploring market dynamics of biological including biosimilar treatments for retinal diseases in Europe: An interrupted time‐series analysis. Acta Ophthalmologica, 104(8), 926-939. https://doi.org/10.1111/aos.70148
Vancouver
Car E, Huys I, Simoens S, Vulto AG. Exploring market dynamics of biological including biosimilar treatments for retinal diseases in Europe: An interrupted time‐series analysis. Acta Ophthalmologica. 2026;104(8):926-939. doi:10.1111/aos.70148
BibTeX
@article{Car2026,
author = {Car, Elif and Huys, Isabelle and Simoens, Steven and Vulto, Arnold G},
title = {Exploring market dynamics of biological including biosimilar treatments for retinal diseases in Europe: An interrupted time‐series analysis},
journal = {Acta Ophthalmologica},
year = {2026},
volume = {104},
number = {8},
pages = {926--939},
doi = {10.1111/aos.70148}
}
EUVIMED